Lead Product(s) : Clobazam
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Pharmanovia
Deal Size : Undisclosed
Deal Type : Divestment
Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi
Details : Pharmanovia expands its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from Sanofi, including Frisium (clobazam), Gardenal (phenobarbital), Tercian (cyamemazine), Stemetil, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, N...
Product Name : Frisium
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 18, 2023
Lead Product(s) : Clobazam
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Pharmanovia
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Partnership
Sanofi and Cipla Form Exclusive Distribution Partnership for CNS Portfolio in India
Details : Cipla will distribute and promote Sanofi India's CNS product range, including Frisium (clobazam), an anti-epileptic medication, in India.
Product Name : Frisium
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 27, 2024
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : LGS Foundation
Deal Size : $0.1 million
Deal Type : Partnership
Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
Details : SYMPAZAN (clobazam) is the first and only FDA-approved oral film formulation of clobazam, a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
Product Name : Sympazan
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 17, 2023
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : LGS Foundation
Deal Size : $0.1 million
Deal Type : Partnership
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent
Details : Sympazan® (clobazam), oral film developed with PharmFilm® technology, is a prescription medicine used to treat seizures associated with Lennox-Gastaut Syndrome in people 2 years of age or older. Clobazam positive allosteric modulator of GABA receptor.
Product Name : Sympazan
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 09, 2023
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Assertio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
Details : Under the terms of the definitive agreement, Aquestive exclusively licensed the product’s intellectual property to Assertio for an upfront payment. Aquestive also entered into a long-term supply agreement with Assertio for Sympazan (clobazam) oral film...
Product Name : Sympazan
Product Type : Controlled Substance
Upfront Cash : $9.0 million
October 27, 2022
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Assertio Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy
Details : Clobazam is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Epilepsy.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 04, 2016
Details : Clobazam is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsies, Myoclonic.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 11, 2014
Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
Details : Clobazam is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsies, Myoclonic.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 25, 2014
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Clobazam Use in Epilepsia Partialis Continua - Pilot Study
Details : Clobazam is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsia Partialis Continua.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 09, 2014
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Onfi (Clobazam) is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug Resistant Epilepsy.
Product Name : Onfi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 30, 2013
Lead Product(s) : Clobazam
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
